Paper Details

  1. Home
  2. Paper Details

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

Author: , AweekaFrancesca, BaughBryan P, BensonConstance A, BrownTodd T, CohnSusan E, CurrierJudith S, FichtenbaumCarl J, GodfreyCatherine, HaasDavid W, KoletarSusan L, KuritzkesDaniel R, LandovitzRaphael J, LeavittRandi Y, LennoxJeffrey L, McComseyGrace A, NaLumine H, OfotokunIghovwerha, PattersonKristine B, PrestiRachel M, RibaudoHeather J, RooneyJames F, SagarManish, SeekinsDaniel

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Three antiretroviral regimens were evaluated for virologic efficacy and tolerability in treatment-naive HIV-infected persons. Over 2 years, all three regimens attained high and equivalent rates of virologic control. Tolerability of regimens containing raltegravir or ritonavir-boosted darunavir was superior to that of the ritonavir-boosted atazanavir regimen.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy is not suitable for all treatment-naive HIV-infected persons. OBJECTIVE: To evaluate 3 nonnucleoside reverse transcriptase inhibitor-sparing initial antiretroviral regimens to show equivalence for virologic effic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/25285539

データ提供：米国国立医学図書館（NLM）

HIV-1 Treatment: A Race Against Time

The global fight against HIV-1 continues, with advancements in antiretroviral therapy (ART) leading to improved outcomes for patients. However, finding the most effective and tolerable treatment regimens remains a crucial challenge. This study evaluates the efficacy and tolerability of three different nonnucleoside reverse transcriptase inhibitor-sparing ART regimens for treatment-naive individuals with HIV-1.

The study compared three regimens containing different combinations of antiretroviral medications: atazanavir/ritonavir, raltegravir, and darunavir/ritonavir. The researchers found that all three regimens were highly effective in suppressing viral load and achieving virologic control over a two-year period. While raltegravir and darunavir/ritonavir exhibited superior tolerability profiles compared to atazanavir/ritonavir, which was associated with a higher incidence of hyperbilirubinemia. The study also found that antiretroviral resistance was rare but more frequent with raltegravir.

This study provides valuable insights into the comparative efficacy and tolerability of different ART regimens for treatment-naive individuals with HIV-1. It highlights the importance of selecting regimens that optimize virologic control while minimizing adverse effects.

Navigating the Complexities of HIV-1 Treatment

This study is like a camel caravan traversing a vast desert of HIV-1 treatment options. The researchers meticulously evaluate different ART regimens, seeking the most effective and tolerable path for patients.

Finding the Right Path to Viral Suppression

This research emphasizes the importance of personalized treatment approaches for HIV-1. The study's findings suggest that careful consideration should be given to the individual patient's risk factors, potential side effects, and tolerability when selecting an ART regimen.

Dr.Camel's Conclusion

The research on HIV-1 treatment is like a camel caravan navigating a vast desert of medical complexities. The researchers meticulously evaluate different ART regimens, seeking the most effective and tolerable path for patients. The study's findings provide valuable insights for optimizing treatment strategies and improving patient outcomes.

Date :
  1. Date Completed 2015-02-19
  2. Date Revised 2022-04-14
Further Info :

Pubmed ID

25285539

DOI: Digital Object Identifier

NIHMS637050

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.